The U.S. Food and Drug Administration concluded 2025 with a significant surge of new cancer treatment approvals, granting more than 20 in the final quarter alone. This brought the annual total to over 50 oncology approvals, highlighting a year of rapid progress across multiple cancer types, from blood cancers to solid tumors.
A key development was the expansion of a new drug class targeting acute myeloid leukemia (AML). The agency approved a new indication for revumenib and cleared a second menin inhibitor. These drugs block the menin protein, disrupting a complex that drives cancer-promoting gene expression in leukemias with specific genetic mutations, such as those in the NPM1 gene. In multiple myeloma, a landmark approval provided the first treatment option for the asymptomatic, smoldering stage. This formulation of daratumumab with hyaluronidase is administered subcutaneously and works by binding to the CD38 protein on abnormal plasma cells to induce cell death, potentially delaying progression to active disease.
The quarter also saw important advances in treating lung cancer and addressing rare tumors. Two new therapeutics were approved for different forms of lung cancer, one of the nation's most common malignancies. Furthermore, the FDA expanded the use of selumetinib, a MEK inhibitor, to include certain adult patients. This drug targets proteins in the MAPK signaling pathway to shrink tumors known as plexiform neurofibromas, which can cause severe pain and functional impairment.
For prostate cancer patients, a new treatment avenue opened with the first approval of a PARP inhibitor for cancers with specific DNA repair mutations that are still sensitive to hormone therapy. This targets a vulnerability in approximately one-quarter of metastatic cases. The immunotherapy landscape also broadened, with new indications issued for three immune checkpoint inhibitors, one cell-based therapy, and one T-cell engager. Additionally, the FDA converted several accelerated approvals to traditional approvals after confirmatory trials verified clinical benefit, solidifying the role of these therapies.
Looking ahead, this concentrated wave of approvals and expanded indications provides oncologists and patients with a broader, more precise arsenal. The continued conversion of accelerated approvals underscores a commitment to confirming the long-term value of new therapies, offering sustained hope for improved outcomes across a widening spectrum of cancers.